SCHEMBL2385340

SCHEMBL2385340

Cc1ccc2c(c1)c(O)c(C(=O)NC(C)C(=O)O)c(=O)n2C

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.55
NPC1 O15118 5/20 0.50
RAB9A P51151 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
NLRP3 Q96P20 2/20 0.49
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HIF1A Q16665 3/20 0.46
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
KDM4E B2RXH2 3/20 0.43
EGLN1 Q9GZT9 1/20 0.42
GSK3B P49841 4/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HTT P42858 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385339 1.00 L3MBTL1 (0.55) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL2382746 0.91 L3MBTL1 (0.55) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL2382749 0.91 L3MBTL1 (0.55) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL12254498 0.91 L3MBTL1 (0.52) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL2384516 0.87 L3MBTL1 (0.54) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL15419106 0.87 GSK3B (0.56) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL2384512 0.87 L3MBTL1 (0.54) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL15419151 0.87 GSK3B (0.56) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL2385208 0.87 L3MBTL1 (0.54) L3MBTL1NPC1RAB9AMEN1KMT2A
SCHEMBL2385209 0.87 L3MBTL1 (0.54) L3MBTL1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP claimed
US-8017626-B2 Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-13 US disclosed
US-8012968-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. (US) 2011-09-06 US disclosed
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-09-23 US disclosed
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. 2010-07-22 US disclosed
US-7728130-B2 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity AMGEN INC. (US) 2010-06-01 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184763-A1 QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 L3MBTL1 4035/4885NPC1 2913/4885RAB9A 3734/4885
US-20100240610-A1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF EGLN3, HIF1AN, EGLN2 L3MBTL1 4024/4885NPC1 2775/4885RAB9A 3405/4885
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof EGLN3, HIF1AN, EGLN2 L3MBTL1 4024/4885NPC1 2775/4885RAB9A 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.